CT109 SN38
Alternative Names: CT109-SN-38Latest Information Update: 20 Jan 2023
At a glance
- Originator Stromatis Pharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Pancreatic cancer
Most Recent Events
- 09 Dec 2022 Preclinical trials in Colorectal cancer in USA (Parenteral)
- 09 Dec 2022 Preclinical trials in Pancreatic cancer in USA (Parenteral)
- 09 Dec 2022 Pharmacodynamics data from a preclinical trial in Pancreatic ductal adenocarcinoma (PDAC) and Colorectal cancer (CRC) presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)